Data / Form D filings / Revance Therapeutics, Inc.
Revance Therapeutics, Inc.: Form D filings
Revance Therapeutics, Inc., a pharmaceuticals company in Newark, CA, filed 11 Form D notices with the SEC between 2009 and 2013. The latest, on October 23, 2013, reports $10 million sold of a $30 million offering to 4 investors.
Find out what Revance Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 7555 GATEWAY BLVD., Newark, CA, 94560
- Phone
- (510) 742-3400
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1479290
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Oct 23, 2013 | New notice | $30,000,000 | $10,000,000 | $20,000,000 | 4 | Oct 8, 2013 | sec.gov |
| Feb 22, 2013 | New notice | $60,000,000 | $5,000,001 | $54,999,999 | 4 | Feb 5, 2013 | sec.gov |
| Jan 9, 2013 | Amendment | $63,360,183 | $63,360,183 | $0 | 33 | Jan 24, 2011 | sec.gov |
| Sep 14, 2012 | Amendment | $50,919,191 | $50,919,191 | $0 | 33 | Jan 24, 2011 | sec.gov |
| Oct 6, 2011 | New notice | $1,200,000 | $0 | $1,200,000 | 1 | Sep 20, 2011 | sec.gov |
| Jun 14, 2011 | Amendment | $45,000,000 | $45,000,000 | $0 | 23 | Jan 24, 2011 | sec.gov |
| Feb 3, 2011 | New notice | $15,000,000 | $5,000,000 | $10,000,000 | 23 | Jan 24, 2011 | sec.gov |
| Nov 18, 2010 | Amendment | $36,236,932 | $36,236,932 | $0 | 27 | Dec 8, 2009 | sec.gov |
| Aug 23, 2010 | Amendment | $34,436,965 | $34,436,965 | $0 | 18 | Dec 8, 2009 | sec.gov |
| Jun 1, 2010 | Amendment | $33,436,970 | $33,436,970 | $0 | 16 | Dec 8, 2009 | sec.gov |
| Dec 23, 2009 | New notice | $25,622,090 | $25,622,090 | $0 | 15 | Dec 8, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ronald L. Eastman | Director | |
| Frank L. Kung | Director | |
| Phyllis L. Gardner | Director | |
| Jonathan L. Tunnicliffe | Director | |
| Daniel L. Browne | Executive Officer, Director | |
| Vicente L. Trelles | Director | |
| Robert L. Byrnes | Director | |
| Jim L. Glasheen | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Oct 21, 2013 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Revance Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.